Targeting TGFβ activity in pancreatic cancer to improve treatment outcomes
Targeted inhibition in stromal TGFβ activity in pancreatic cancer
This study is looking at how blocking a specific protein called TGFβ in the tissue around pancreatic tumors might help make chemotherapy and immunotherapy work better for people with pancreatic cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-10669058 on NIH RePORTER |
What this research studies
This research investigates how inhibiting TGFβ activity in the supportive tissue surrounding pancreatic tumors can enhance the effectiveness of chemotherapy and immunotherapy. The study focuses on the role of TGFβ in promoting tumor growth and immune suppression, particularly in the context of pancreatic cancer. By selectively blocking TGFβ signaling in stromal cells, the researchers aim to alter the tumor environment to make it less conducive to cancer progression. The approach involves using animal models to understand the mechanisms at play and to evaluate the potential benefits of this targeted therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer, particularly those with specific mutations affecting TGFβ signaling.
Not a fit: Patients with pancreatic cancer who do not have the relevant epithelial mutations in TGFβ signaling may not benefit from this targeted approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for pancreatic cancer patients, improving their response to existing therapies.
How similar studies have performed: While targeting TGFβ in cancer has faced challenges, this approach of selectively inhibiting stromal TGFβ signaling is novel and has shown promise in preclinical models.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Brekken, Rolf a — Ut Southwestern Medical Center
- Study coordinator: Brekken, Rolf a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.